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Reduced expression of the transcription factor PU.1 is frequently associated with development 25 
of acute myeloid leukemia (AML), whereas elevated levels of CITED2 (CBP/p300-interacting-26 
transactivator-with-an-ED-rich-tail 2) enhance maintenance of both normal and leukemic 27 
hematopoietic stem and progenitor cells (HSPCs). Recent findings indicated that PU.1 and 28 
CITED2 act in the same gene regulatory network and we therefore examined a potential 29 
synergistic effect of simultaneous PU.1 downregulation and CITED2 upregulation on stem cell 30 
biology and AML pathogenesis. We found that simultaneous PU.1/CITED2 deregulation in 31 
human CD34+ cord blood (CB) cells, as well as CITED2 upregulation in preleukemic murine 32 
PU.1-knockdown (PU.1KD/KD) bone marrow cells, significantly increased the maintenance of 33 
HSPCs compared to the respective deregulation of either factor alone. Increased replating 34 
capacity of PU.1KD/KD/CITED2 cells in in vitro assays eventually resulted in outgrowth of 35 
transformed cells, while upregulation of CITED2 in PU.1KD/KD cells enhanced their engraftment in 36 
in vivo transplantation studies without affecting leukemic transformation. Transcriptional analysis 37 
of CD34+ CB cells with combined PU.1/CITED2 alterations revealed a set of differentially 38 
expressed genes that highly correlated with gene signatures found in various AML subtypes. 39 
These findings demonstrate that combined PU.1/CITED2 deregulation induces a transcriptional 40 
program that promotes HSPC maintenance which might be a pre-requisite for malignant 41 
transformation.  42 
Highlights 43 
- Simultaneous PU.1 down- and CITED2 upregulation increases human HSPCs 44 
maintenance 45 
- CITED2-overexpression enhances maintenance of murine pre-leukemic PU.1KD/KD 46 
HSPCs  47 
- Gene expression changes in PU.1-low/CITED2-high cells overlap with AML-signatures  48 
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Introduction  49 
Leukemic transformation has been shown to be a multistep process in which hematopoietic cells 50 
acquire multiple mutations/alterations along the differentiation-road that can either influence self-51 
renewing-, differentiation- or proliferation properties of cells.1 Initial mutations are thought to 52 
occur in hematopoietic stem and progenitor cells (HSPCs) which can alter their lifespan and/or 53 
maintenance and lead to clonal hematopoiesis.2,3 Additional mutations in such preleukemic 54 
HSPCs promote leukemic progression.4 A key regulator of hematopoiesis is the ETS-family 55 
transcription factor PU.1 that is expressed at low levels in HSPCs5 and at high levels in the 56 
myeloid linage and B-cells.6–8 PU.1 has crucial functions for both HSPC-maintenance9–14 and 57 
differentiation of the myeloid lineage.15,16 In acute myeloid leukemia (AML), PU.1 expression is 58 
frequently found to be disturbed by mutations, translocations and changes in signal 59 
transduction17–23, which contributes to the accumulation of immature blasts- the characteristic 60 
feature of AML. Notably, heterozygous mutations of the SPI1 gene itself (which is the gene 61 
encoding PU.1) are only rarely found in human AML24,25 and homozygous mutations are not 62 
detected at all, which is in line with murine models demonstrating that total absence of PU.1 is 63 
not compatible with hematopoiesis- whether it is healthy or pathologic.11,26–29 To resemble the 64 
situation observed in patients, mouse models with reduced PU.1 expression rather than full 65 
Spi1-deletions have become useful models to study AML pathogenesis.12,30–32 Homozygous 66 
deletions of a -14-kb upstream regulatory region (URE) in the Spi1 locus results in 80% 67 
reduction of PU.1 expression in murine bone marrow cells and mice develop AML at 68 
approximately 6 months of age. Malignant transformation in PU.1-knockdown mice was found to 69 
be recurrently accompanied by chromosomal aberrations30, indicating that PU.1-low cells are 70 
more vulnerable for acquiring additional changes that promote leukemia development. Since 71 
PU.1 knockdown mice undergo a preleukemic phase of several months they can also serve as a 72 
model for studying alterations that precede leukemic transformation and identify cooperative 73 
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factors that accelerate or facilitate transformation. In particular, additional alterations that lead to 74 
an increased maintenance of PU.1-low HSPCs could contribute to expansion of a cell pool that 75 
is susceptible to mutation acquisition and thereby promote AML development. 76 
We recently demonstrated that PU.1 negatively regulates the expression of the transcriptional 77 
co-activator CITED2 (CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) by binding to 78 
multiple ETS-binding sites in the CITED2 promoter.33 CITED2 is a key guardian of hematopoietic 79 
stem cell (HSC) maintenance and its deletion in murine HSC results in increased cell apoptosis, 80 
cycling and consequently multi-lineage bone marrow failure.34–36 Notably, CITED2 has also 81 
important functions for the survival of leukemic stem cells33,37 and pathways that are involved in 82 
upregulating CITED2 expression37–42 are frequently activated in AML. Therefore, we studied the 83 
combined de-regulation of PU.1 and CITED2 in normal and leukemic HSPCs. 84 
Here we show that simultaneous upregulation of CITED2 and downregulation of PU.1 in human 85 
CD34+ cord blood cells using lentiviral constructs enhances the maintenance of hematopoietic 86 
stem and progenitor cells (HSPC). Similar, CITED2 overexpression in preleukemic murine PU.1-87 
knockdown bone marrow cells increased replating capacity and enhanced engrafted cells in 88 
transplantation assays, without affecting the transforming event. In summary, our data indicate 89 
that combining downregulation of PU.1 and upregulation of CITED2 enhances the lifespan of 90 
PU.1-low HSCs, which makes them more prone to full leukemic transformation. 91 
Material and Methods 92 
Isolation of stem- and progenitor cells 93 
Neonatal cord blood was derived from healthy full-term pregnancies after informed consent from 94 
the Obstetrics departments of the Martini Hospital and University Medical Center in Groningen, 95 
The Netherlands. Mononuclear cells were isolated by density gradient centrifugation using 96 
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Lymphoprep (Alere Technologies AS, Oslo, Norway) and CD34+ cells were selected using the 97 
MACS CD34 microbead kit on autoMACS (Miltenyi Biotec, Leiden, The Netherlands). Lentiviral 98 
constructs and transduction procedure are described in the Supplementary information. 99 
CFC assay  100 
Transduced human CD34+ cord blood cells were directly sorted in MethoCult H4230 (StemCell 101 
Technologies, Grenoble, France) supplemented with 19% (v/v) IMDM, 20 ng/mL IL-3, 20 ng/mL 102 
IL-6, 20 ng/mL G-CSF, 20 ng/mL SCF (Novoprotein) and 1 U/mL EPO (EPREX). Murine BM 103 
cells were isolated from 8-12 weeks old B6.J URE-/- mice.30 Lineage depleted murine BM cells 104 
were transduced as described above and c-Kit+ cells were directly sorted into MethoCult H4230 105 
(StemCell Technologies) supplemented with 19% (v/v) IMDM (Lonza, Breda, The Netherlands), 106 
100 ng/ml mSCF (PepProtech), 20 ng/ml hGM-CSF, 2 ng/ml mIL-3 (PepProtech). Colonies were 107 
scored after 12-14 days of incubation. Subsequently, 50000 cells were replated and again 108 
scored after 12-14 days.  109 
Long-term cultures on stroma  110 
Murine MS5 cells were expanded and cultured as described earlier.43 Long-term Culture-111 
Imitating Cell (LTC-IC) assays were performed by plating transduced CD34+ cord blood cells in 112 
limiting dilutions in the range of 9 to 1000 cells per well on MS5 stromal cells in 96-well plates in 113 
LTC medium (αMEM supplemented with heat-inactivated 12.5% FCS, heat-inactivated 12.5% 114 
horse serum (Sigma, Zwijndrecht, The Netherlands), 100 U/mL penicillin/streptomycin, 200 mM 115 
glutamine, 57.2 μM β-mercaptoethanol [Sigma] and 1 μM hydrocortisone [Sigma]). After 5 116 
weeks, methylcellulose (MethoCult H4230 supplemented with 19% (v/v) IMDM, 20 ng/mL IL-3, 117 
20 ng/mL IL-6, 20 ng/mL G-CSF, 20 ng/mL SCF and 1 U/mL EPO) was added to the wells. Two 118 
weeks later, wells containing CFCs were scored as positive. LTC-iC frequency was calculated 119 
using the L-Calc software. For MS5 co-culture growth curves, 10-50 x105 cells transduced 120 
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CD34+ cord blood cells were plated on MS5 stromal cells in a T25 culture flask in LTC medium 121 
supplemented with 20 ng/ml IL-3, G-CSF and TPO. Cultures were demi-depopulated weekly for 122 
analysis.  123 
In vivo transplantations into NSG mice  124 
Murine Lin-c-Kit+ BM cells were isolated from 8-12 weeks old B6.J URE-/- mice by means of 125 
lineage depletion (Dynabeads), followed by c-Kit enrichment (MACS). Cells were resuspended 126 
in M5300 medium (StemCell Technologies) supplemented with rmSCF (50 ng/ml), rmTPO (20 127 
ng/ml), rmIL3 (25 ng/ml), rmIL6 (10 ng/ml) and Primocine (anti mycoplasma agent 2ul/ml). The 128 
next day, the cells were in 2 subsequent rounds lentivirally transduced with GFP-tagged control 129 
or CITED2 overexpressing lentivirus in the presence of 4 ng/ml polybrene. After 2 days, 0.2 x106 130 
cells for cohort A and 0.5 x106 cells for cohort B were retro-orbitally injected into NSG mice. 131 
Before transplantations, mice were sublethally irradiated (2.0 Gy). Engraftment was analyzed in 132 
the peripheral blood (PB) and bone marrow (BM) by flow cytometry.  133 
Gene expression profiling 134 
From 4 independent cord blood batches, CD34+ cells were MACS isolated and transduced with 135 
control lentivirus, CITED2 overexpressing lentivirus, a shRNA lentivirus against PU.1 or a 136 
lentivirus containing a CITED2 overexpression cassette and a shRNA against PU.1. After 2 days 137 
transduced CD34+ were sorted from each transduction group (Group 1: Control; Group 2: 138 
CITED2; Group 3: shPU.1; Group 4: CITED2/shPU.1). Total RNA was isolated using the 139 
RNeasy mini kit from Qiagen (Venlo, The Netherlands) according to the manufacturer's 140 
recommendations. Q-PCR analysis was used to validate proper overexpression or knock-down 141 
of CITED2 and PU.1 respectively. RNA from 2 cord bloods with similar overexpression or knock-142 
down of CITED2 and PU.1 was pooled within each group and quality was examined using the 143 
Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Genome-wide 144 
7 
 
expression analysis was performed on Illumina (Illumina, Inc., San Diego, CA, USA) BeadChip 145 
Arrays (Illumina HT12-V4). Typically, 0.5–1 μg of mRNA was used in labeling reactions and 146 
hybridization with the arrays was performed according to the manufacturer's instructions. The 147 
expression was quantile normalized using GeneSpring GX software, and from the probesets that 148 
were expressed above background (set to 25) subsequent fold differences were calculated. 149 
Genes that indicated a fold-change of <2 or >2 were further analyzed. Array data are available at 150 
http://www.ncbi.nlm.nih.gov/geo, with accession code: GSE118036. Array data were compared 151 
to publically available (http://servers.binf.ku.dk/bloodspot/) gene expression data from 198 AML 152 
patients (60 t(8;21); 47 inv(16)/t16;16); 43 t(11q23) and 48 AMLs with complex karyotype) and 153 
18 normal CD34+ subsets.  154 
Immunoblotting 155 
Preparation of cell lysates and immunoblotting procedure was performed as described 156 
previously.44 Primary antibodies for immunoblotting were: MRG1 (JA22, Santa Cruz, #SC-157 
21795), PU.1 (T-21, Santa Cruz, #SC-352). 158 
Statistical analysis 159 
If not indicated otherwise in figure legends, p-values were calculated using the students t-test. 160 
 161 
Results 162 
Combining PU.1 down-regulation with CITED2-upregulation maintains HSCs 163 
In order to investigate the impact of combined deregulation of PU.1- and CITED2 levels on 164 
HSPCs, CD34+ cord blood (CB) cells were isolated and double-transduced with various 165 
combinations of lentiviral constructs to achieve either short hairpin (sh)-mediated PU.1 166 
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downregulation, CITED2 upregulation or a combination of both. For all conditions, we observed 167 
20-25 percent double-transduced cells, and three days after transduction, cells were sorted and 168 
plated for colony forming cell (CFC) assays (Figure 1A, Supplementary Figure S1A-B). Levels of 169 
PU.1 reduction and CITED2 overexpression were confirmed by both Q-PCR and western blot 170 
(Figure 1B, Supplementary Figure S1C). The shPU.1-, CITED2- and shPU1/CITED2- 171 
transduced cells provided comparable CFU-GM, BFU-E and CFU-GEMM colony formation 172 
compared to control cells (Figure 1C-D). However, replating experiments showed increased 173 
replating capacity of shPU.1/CITED2 cells which could not be achieved by altering levels of PU.1 174 
or CITED2 only (Figure 1E).  Furthermore, we showed that the enhanced replating capacity of 175 
shPU.1/CITED2 cells is restricted to the CD34+CD38- fraction (Figure 1F-G), which suggests 176 
that it is primarily the more immature fraction of HSPCs that is maintained by simultaneous 177 
alterations of CITED2- and PU.1 expression levels.   178 
 179 
Simultaneous PU.1 down and CITED2 upregulation increases LTC-iC frequency 180 
To address the question if combined PU.1/CITED2 deregulation can also impact long-term 181 
functions of HSPCs, control-, shPU.1-, CITED2- and shPU1/CITED2- transduced CD34+ CB 182 
cells were cultured on a MS5 stromal layer in the presence of cytokines for up to 4 weeks and 183 
subsequently plated for CFC assays (Figure 2A). Total cell numbers of shPU.1-, CITED2- and 184 
shPU1/CITED2- cells in MS5 co-cultures were not different compared to control cells (Figure 185 
2B), indicating that growth factor-induced HSPC expansion was not significantly affected by 186 
PU.1/CITED2 deregulation. Cells that were plated in methyl cellulose after 3 or 4 weeks of 187 
culturing formed equal number of colonies in CFC assays (Figure 2C), however, replating of 188 
CFC assays with shPU1/CITED2 cells resulted in a significantly higher number of colonies 189 
compared to all other conditions (Figure 2D). Remarkably, colony formation in 2nd round of 190 
replating was solely restricted to shPU1/CITED2 cells (Figure 2D). The impact of PU.1/CITED2 191 
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deregulation on HSPC maintenance was further evaluated by performing Long-Term Culture-192 
initiating Cell (LTC-iC) assays, in which cells are maintained for 5 weeks on a MS5 stromal layer 193 
without additional growth factors prior to reading out their colony forming capacity (Figure 2E). 194 
Whereas PU.1 downregulation did not alter the LTC-IC frequency significantly compared to 195 
control cells, upregulation of CITED2 resulted in a 4-fold increase, and combined 196 
shPU.1/CITED2 alteration in an 8-fold increase of the LTC-iC frequency (Figure 2F-G). These 197 
data indicate that upregulation of CITED2 alone can be sufficient to increase HSPC 198 
maintenance under certain conditions. However, if HSPC maintenance is challenged by external 199 
signals such as activation of signalling cascades that promote cell proliferation or differentiation, 200 
simultaneous downregulation of PU.1 and upregulation of CITED2 can increases the HSPC 201 
frequency more effectively. 202 
 203 
CITED2 overexpression in PU.1KD/KD bone marrow cells enhances the outgrowth of 204 
immature cells in in vitro replating assays 205 
To confirm and study the effects of CITED2 upregulation in cells with low PU.1 expression with 206 
an alternative strategy, we lentivirally overexpressed CITED2 in murine PU.1KD/KD  bone marrow 207 
(BM) cells, which have the potential to transform and are therefore pre-leukemic.30 Reduction of 208 
PU.1 expression in PU.1KD/KD cells compared to PU.1WT/WT cells was confirmed by Q-PCR 209 
(Supplementary Figure S2A). Lineage-depleted PU.1KD/KD BM cells were isolated from mice in a 210 
pre-leukemic phase (n=6) and control- or CITED2 transduced cells were sorted in 211 
methylcellulose to perform CFC-assays with subsequent replating (Figure 3A). Similar to the 212 
experiments performed with CB cells, we observed comparable numbers of CFC’s in control- 213 
and CITED2 transduced cells in the primary CFC assay, whereas CITED2 overexpression 214 
resulted in significantly more colonies following the 1st replate (p<0.05; Figure 3B). 215 
Phenotypically we did not observe differences in control- vs. CITED2 colonies (Supplementary 216 
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Figure S2B). Interestingly, in the 2nd and 3rd replate, samples could be divided in 2 groups based 217 
on colony number and replating ability. With cells obtained from 4 mice (group 1), colony 218 
formation could be observed in 3 rounds of replates with higher colony numbers in CITED2- 219 
compared to control samples (in average 69 vs 5 colonies in 2nd replate, p=0.05; Figure 3B). In 220 
group 2 both control- and CITED2-transduced cells gave rise to several hundred colonies even 221 
in a 3rd replate (Figure 3B). Notably, group 1 and 2 showed similar transduction efficiencies at 222 
the moment of cell sorting. Cytospins of CFC’s showed presence of mature cells in the 1st 223 
replate of group 1, whereas the 3rd replate was dominated by cells with immature morphology 224 
with a number of blast cells (Figure 3C). In contrast, a phenotypically homogenous population of 225 
immature blast cells was already present in the 1st replates of group 2 (Figure 3C), which 226 
contained c-Kitpos/Gr-1neg and c-Kitpos/Gr-1low cell populations (Supplementary Figure S2C). By 227 
flow cytometric analysis for c-Kit and Sca-1 expression, we observed that colonies from replates 228 
of control cells mainly consist of a rather homogenous c-KitlowSca-1neg cell population (Figure 229 
3D), whereas colonies from CITED2-transduced cells showed a more heterogeneous pictures 230 
consisting of c-Kitlow, c-Kithigh, and c-Kithigh/Sca-1pos cells (Figure 3D-E). Based on these data we 231 
concluded that CITED2 is not required or additive to leukemic transformation, but potentially 232 
supports the outgrowth of phenotypically immature PU.1KD/KD cells, at least for the time frame we 233 
performed the experiments.  234 
 235 
Overexpression of CITED2 in PU.1KD/KD is not sufficient for leukemia initiation in vivo 236 
Next, we questioned whether overexpression of CITED2 in murine PU.1KD/KD cells contributes to 237 
leukemia development in vivo. Therefore, c-Kitpos-HSPCs were isolated from PU.1KD/KD donor 238 
mice and transduced with control or CITED2 overexpressing lentivirus (Supplementary Figure 239 
S3A). Subsequently, transduced cells were transplanted into irradiated NSG recipient mice 240 
(Figure 4A). Two independent experiments (referred to as cohort A and B) were performed with 241 
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each cohort consisting of 7 mice receiving control-transduced cells and 7 mice receiving 242 
CITED2-transduced cells. In both cohorts, we observed a significantly higher percentage of 243 
CITED2-GFP donor cells compared to control-GFP donor cells in the peripheral blood of 244 
recipient mice 11-15 weeks after injection (Figure 4B). However, only modestly higher levels of 245 
CITED2-GFP compared to control-GFP donor cells were found in the bone marrow of recipient 246 
mice after 34 weeks (cohort A) and 24 weeks (cohort B) respectively (Figure 4C), which were 247 
non-significant differences. In none of the mice signs of leukemia development were observed, 248 
as indicated by normal weight of spleen and liver (Figure 4D, Supplementary Figure S3D). 249 
These data indicate that CITED2-GFP PU.1KD/KD donor c-Kitpos-HSPCs contribute faster to 250 
engraftment than control-GFP PU.1KD/KD cells, however, CITED2 overexpression does not 251 
enhance the initiation of leukemia within this time frame.  252 
 253 
shPU.1/CITED2-induced gene expression patterns correlate with gene expression profiles 254 
observed in AML 255 
In order to investigate the transcriptional changes caused by shPU.1/CITED2 gene deregulation, 256 
an Ilumina BeadChip array was performed with CD34+ CB cells transduced with the 257 
corresponding lentiviral vectors (Figure 5A, Supplementary Figure S4A-B). PU.1 downregulation 258 
and CITED2 overexpression of sorted cells was verified by Q-PCR (Supplementary Figure S4C). 259 
We found that downregulation of PU.1, overexpression of CITED2 or the combination of both 260 
respectively led to 176, 205 or 148 differentially expressed genes (>2-fold up- or downregulated 261 
in both replicates, Figure 5B), as compared to control transduced cells. Notably, the 148 probe 262 
sets that were found differently expressed in shPU.1/CITED2 cells, were partly overlapping with 263 
deregulated genes found in shPU.1- or CITED2 only cells (32/148 overlap with shPU.1; 35/148 264 
overlap with CITED2), but also contained a unique set of genes (94/148). (Figure 5B, 265 
Supplementary Table S1). In general, gene expression changes were surprisingly modest and 266 
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unexpectedly, both pathway- and GSEA analysis did not reveal significant signatures linked to 267 
stem cell maintenance or cell proliferation. Despite these findings, we decided to explore 268 
whether gene expression changes induced by combined shPU.1/CITED2 deregulation overlap 269 
with changes observed in CD34+ AML cells in comparison to normal CD34+ cells. We therefore 270 
downloaded gene expression data from 198 AML patients and 18 normal CD34+ subsets from 271 
the BloodSpot database (http://servers.binf.ku.dk/bloodspot/). 112/148 probesets from our study 272 
could be linked to a gene, of which 67 were present in the BloodSpot database. Of these 67 273 
genes, 34 were upregulated and 33 genes were downregulated in shPU.1 /CITED2-transduced 274 
cells from our study. Notably, we observed that the majority of genes that were found 275 
upregulated in our shPU.1/CITED2 cells are also upregulated in AML patients (29/34), whereas 276 
14 out of 33 downregulated genes in shPU.1/CITED2 cells are also found downregulated in AML 277 
patients when compared to normal CD34+ cells (Figure 5C). A Spearman’s ranked correlation 278 
analysis demonstrated that the gene expression changes we observed in shPU.1/CITED2 cells 279 
significantly correlated with the changes observed in AML (Figure 5D), with the highest 280 
correlation observed for upregulated genes. The overlap of gene expression patterns of 281 
shPU.1/CITED2 cells and AML patients was not specific for a certain subtype of AML but could 282 
be found across various AML patients, suggesting that the modest transcriptional changes 283 
caused by combined PU.1/CITED2 deregulation could be generally supportive for AML 284 
development when combined with variable additional hits.  285 
 286 
Discussion 287 
In the present study we demonstrated that combined upregulation of CITED2 and 288 
downregulation of PU.1 increases HSPC maintenance using two alternative approaches. 289 
Simultaneous overexpression of CITED2 and knockdown of PU.1 in CD34+ cord blood cells 290 
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using lentiviral vectors resulted in enhanced replating capacity in CFC-assays and increased the 291 
LTC-IC frequency. Similar results were obtained when CITED2 was upregulated in preleukemic 292 
murine PU.1KD/KD c-Kitpos-HSPCs.  293 
AML is characterized by a stepwise accumulation of genetic and epigenetic alterations that first 294 
result in the generation of a clonal and/or preleukemic state before eventually leading to fully 295 
transformed leukemic cells. Altered regulation of self-renewal, maintenance and proliferation 296 
without a block in differentiation have been described as an early event in malignant 297 
transformation.2,3,45–47 Recently, several studies have shown that clonal hematopoiesis with 298 
driver mutations can be detected in a large cohort of elderly patients whereby clonal cells 299 
outcompete the remaining cells. However, only a limited number of these patients develop AML, 300 
in particular when co-mutations occur, thereby triggering alternative pathways and making the 301 
cells prone for AML transformation.4,3,48 Apparently, cord blood shPU.1/CITED2 HSCs mimic the 302 
initial step in clonal evolution, reflected by increased replating capacity, increased LTC-IC 303 
frequency, but not a block in differentiation. 304 
Since CITED2 expression is found upregulated in AML and was shown to be essential for 305 
leukemic cell survival33,37 we wondered if CITED2 overexpression in definite preleukemic cells 306 
contributes to their transformation. Knockdown of PU.1 in murine HSCs results in AML 307 
development after undergoing a preleukemic phase of several months30,31, and therefore 308 
untransformed PU.1KD/KD cells resemble such a condition. The results of the present study 309 
demonstrate that overexpression of CITED2 in untransformed PU.1KD/KD c-Kitpos-HSPCs is not 310 
sufficient for immediate leukemia onset, however, expands the pool of preleukemic PU.1KD/KD 311 
HSPCs. An interesting question that could be addressed in future studies is whether 312 
upregulation of CITED2 in PU.1KD/KD cells prior to (serial) transplantation-experiments would 313 
have an impact on AML development or LSC maintenance when combined with additional 314 
alterations. Other mutations have been identified that accelerate the process of leukemic 315 
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transformation when combined with PU.1 downregulation. For instance, mice carrying a 316 
mutation in K-Ras rapidly progress from a myeloproliferative neoplasm to an aggressive AML 317 
when deleting a deubiquitylase that regulates PU.1 stability.23 In addition, in mice with a 318 
homozygous deletion of Msh2, a gene involved in DNA mismatch repair, slight reductions in 319 
PU.1 levels were shown to promote AML progression.32 Similarly, reduction of PU.1 levels in 320 
p53-/- mice resulted in AML development, which is not observed when only p53 is deleted.49 321 
Mechanistically, the importance of CITED2 in maintaining both HSCs and LSCs has been linked 322 
to cell apoptosis in a p53-dependent manner.35 We have shown previously that loss of CITED2 323 
triggers leukemic cells death trough stabilisation of p53,44 an observation also made for other 324 
types of cancer.50 It is likely that the reverse might occur in the context of CITED2 325 
overexpression, making HSC less sensitive to stress response pathways and facilitating the 326 
process of stem cell maintenance.  327 
The PU.1KD/KD HSPCs showed up to 80% reduction of PU.1 levels, whereas our lentiviral-328 
mediated PU.1 knockdown in cord blood cells ranged between 20%-50% reduction in PU.1 329 
levels (Supp. Figure S4C). Strikingly, despite the variability of PU.1 downregulation, both genetic 330 
models resulted in similar phenotypes. These data indicate that already a modest reduction of 331 
PU.1 levels, which is also observed in AML cells,18,19,21,22,24 can lead to an increased HSPC 332 
maintenance in combination with elevated CITED2 levels. We therefore also aimed to get more 333 
insight in the transcriptional changes observes in shPU.1/CITED2 cells. Gene expression 334 
analysis revealed that there are a number of genes differentially expressed in shPU.1/CITED2 335 
CD34+ cord blood cells, which are not deregulated when only PU.1- or CITED2 levels are 336 
altered, indicating that a unique transcriptional program is altered by combined shPU.1/CITED2 337 
alteration. Furthermore, we found that gene expression changes in shPU.1/CITED2 CD34+ cells 338 
mimic a pattern found in patients with various AML subtypes, indicating that our genetic model of 339 
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combined PU.1/CITED2 deregulation resembles a state that is in general supportive for AML 340 
development.  341 
In summary, our genetic models with combined CITED2/PU.1 deregulation mimic the initial step 342 
in clonal leukemia evolution and can serve as useful tools to further study and understand the 343 
molecular mechanism of AML development.  344 
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Figure legends 507 
Graphical abstract Simultaneous downregulation of the transcription factor PU.1 and 508 
upregulation of CITED2 increases the maintenance of hematopoietic stem and progenitor cells 509 
(HSPCs). Since cells with low PU.1 levels are considered to be potential preleukemic, combined 510 
PU.1/CITED2 deregulation increases the pool of HSPCs that might be prone for leukemic 511 
transformation. 512 
Figure1 Combining PU.1 down-regulation with CITED2-upregulation maintains HSCs (A) 513 
Schematic overview of experimental design. Isolated CD34+ cord blood (CB) cells were 514 
transduced with indicated combinations of lentiviral constructs and double-positive cells were 515 
sorted for CFC assays (B) Downregulation of PU.1 and upregulation of CITED2 by our lentiviral 516 
vectors was verified by western blot in the Molm13 leukemic cell line. (C, D) CFC assays 517 
performed with transduced CD34+ CB cells. Relative percentage of indicated colony types (C) 518 
and total number of colonies (D) scored after 14 days is shown. (E) Colonies from primary CFC 519 
assays were harvested and 50000 cells were replated. Total amount of colonies after 14 days is 520 
shown. (F, G) Colony number in CFC assays (F) and replates (G) of transduced CD34+CD38- 521 
and CD34+CD38+ cell population. (D-G) Error bars indicate s.d. of 3 individual experiments 522 
performed in duplicates. Each experiment was performed with CD34+ cells from 2-3 donors. 523 
n.s.= not significant; **P<0.01 compared to control; 524 
 525 
Figure2 shPU.1/CITED2 cells contain the highest LTC-IC frequency (A) Schematic overview 526 
of experimental design. CD34+ cord blood (CB) cells were transduced with indicated lentiviral 527 
constructs and plated on a MS5 stromal layer. After 3-4 weeks, CFC assays were performed 528 
from cultured cells. (B) Growth curve of transduced CD34+ cells cultured on a MS5 stromal layer 529 
in Gartners medium. Error bars indicate s.d. of 6 individual experiments. Each experiment was 530 
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performed with CB from several donors. (C) CFC assays of transduced CB cells that have been 531 
cultured as in (B) for 3 or 4 weeks. Error bars indicate s.d. of 3 individual experiments performed 532 
in duplicates. n.s.= not significant. (D) 1st and 2nd replate of cells harvested from CFC assays 533 
shown in (C). Error bars indicate s.d. of 3 individual experiments performed in duplicates. n.s.= 534 
not significant, *P<0.05 (E) Experimental design of Long-term Culture-Initiating Cell (LTC-iC) 535 
assay: Transduced CD34+ CB cells were sorted in a MS5-coated 96 well plate in limiting 536 
dilutions of 9-1000 cells. After 5 weeks, methylcellulose was added and wells were scored as 537 
positive or negative for colony forming units (CFU) after 14 days to determine LTC-iC 538 
frequencies. (F) Scoring of 1 representative LTC-iC experiment performed as described in (E). 539 
(G) Average LTC-IC frequency of 3 individual experiments is shown. Each individual experiment 540 
was performed with CD34+ cells from serval donors. Error bars indicate s.d.; n.s.= not significant, 541 
*P<0.05. 542 
 543 
Figure 3 Overexpression of CITED2 in murine PU.1KD/KD bone marrow cells maintains stem- 544 
and progenitor cells prior to transformation (A) Schematic overview of experimental design. 545 
Lineage depleted bone marrow (BM) cells derived from PU.1KD/KD mice were transduced with 546 
control or CITED2 overexpressing lentivirus and sorted cells were applied to CFC assays and 547 
subsequent replating. (B) Number of colonies in CFC assays and replates performed with 548 
PU.1KD/KD cells transduced with control- or CITED2 constructs. Data points connected by a black 549 
line belong to cells isolated from the same mouse. Data from 6 individual experiments using BM 550 
from 6 individual mice are shown. Samples were separated in 2 groups based on colony 551 
number, group 2 is labelled by a red border. *P<0.05. (C) May Grunwald/Giemsa staining of 552 
cells harvested from CFC assays performed in (B); scale bars: 10 µm. (D) Representative FACS 553 
plots indicating c-Kit and Sca-1 expression of lineage negative control- and CITED2 transduced 554 
PU.1KD/KD cells harvested from CFC assay replates shown in (B). Plots of 2 mice from group 2 555 
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are shown (#1, #2). Numbers in gates indicate percentage of c-Kit-, c-Kit+, c-Kit++ and c-556 
Kit++/Sca-1+ double pos. cell populations. (E) Graph indicating the percentage of c-Kit++ and c-557 
Kit++/Sca-1+ cell fractions observed by FACS analysis as described in (D); group 2 samples are 558 
labelled by a red border; n=5, *P<0.05.  559 
 560 
Figure 4 Overexpression of CITED2 in PU.1KD/KD HSCs is not sufficient for leukemic 561 
transformation (A) Schematic overview of experimental design. Lin-cKit+ BM donor cells from 562 
PU.1KD/KD mice were transduced with a GFP-tagged control or CITED2 lentivirus and retro-orbital 563 
injected into irradiated NSG recipient mice. 2 independent experiments (referred as cohort A and 564 
B) were performed with 7 control- and 7 CITED2- recipient mice each being injected. (B) 565 
Percentage of GFP+CD45.2 cells at time of injection and in peripheral blood after indicated 566 
number of weeks is shown. Error bars indicate s.d.; n=7 for each cohort; *P<0.05. (C) 567 
Percentage of GFP+ cells in bone marrow of recipient mice at day of sacrifice 30-34 weeks after 568 
injection is shown. Error bars indicate s.d.; n=14; (D) Spleen weights of sacrificed mice is 569 
indicated; Error bars indicate s.d. 570 
 571 
Figure 5 Combining PU.1 down-regulation with CITED2-upregulation induces a gene 572 
expression pattern also observed in AML (A) Schematic overview of experimental design. 573 
Isolated CD34+ cord blood cells were transduced with indicated lentiviral constructs and 574 
transduced CD34+ cells were sorted for Illumina BeadChip Arrays (B) VENN diagram indicating 575 
the number of genes changed >2-fold in duplicate arrays, compared to control transduced cells 576 
(C) Gene expression comparison of non-APL AMLs vs. normal CD34+ cells. Each column is an 577 
AML sample with the red squares at the top indicating the subtype. (D) Spearman’s rank 578 
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correlation between genes that are differentially expressed in shPU.1/CITED2 cells and genes 579 
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Supplementary Figure S1 (Supplement to Figure 1) 7 
Combined PU.1 down-regulation and CITED2-upregulation in CD34+ cord blood cells was mediated by 8 
lentiviral constructs 9 
(A) Schematic overview of the lentiviral constructs used for transduction (B) Double transduction 10 
strategy with indicated constructs was performed to achieve either downregulation of PU1 (shPU.1), 11 
upregulation of CITED2 (CITED2) or a combination of both (shPU.1/CTED2). (C) Efficiency of lentiviral 12 
constructs was tested by Q-PCR using CD34+ cord blood cells that had been transduced with indicated 13 
constructs and sorted for double transduced cells. The level of SPI1 (PU.1) downregulation varied 14 




Supplementary Figure S2 (Supplement to Figure 3) 19 
Overexpression of CITED2 in PU.1KD/KD cells 20 
(A) Q-PCR for Spi1 confirming an 80% reduction of Spi1 (PU.1) expression in PU.1KD/KD BM cells compared 21 
to PU.1WT/WT cells. Error bars indicate s.d. of Q-PCR triplicates (B) Pictures show colonies from control- or 22 
CITED2 transduced PU.1KD/KD cells in primary CFC assays (upper panel) or 2nd round of replating. (C) FACS 23 
plots indicating c-Kit and Gr-1 expression of control- or CITED2 transduced PU.1KD/KD cells that have been 24 
harvested from CFC assay replates. Two samples of group 2, which is the group characterized by very 25 




Supplementary Figure S3 (Supplement to Figure 4) 30 
Overexpression of CITED2 in PU.1KD/KD HSCs is not sufficient for leukemic transformation  31 
(A) Schematic overview of the lentiviral constructs used for transduction (B) Percentage of CD45.2 cells 32 
in peripheral blood after indicated number of weeks is shown. Error bars indicate s.d.; n=7 for each 33 
cohort; (C) Percentage of CD45.2 cells in bone marrow of recipient mice at day of sacrifice 30-34 weeks 34 
after injection is shown. Error bars indicate s.d.; n=14; (D) Liver weights of sacrificed mice is indicated; 35 




Supplementary Figure S4 (Supplement to Figure 5) 40 
Ilumina BeadChip array was performed with control-, shPU.1-, CITED2, and shPU.1/CITED2 CD34+ CB 41 
cells 42 
(A) Schematic overview of the lentiviral constructs used for transduction (B) Overview of the 43 
experimental procedure: 4 different cord blood samples were transduced with the indicated constructs 44 
to achieve either downregulation of PU1 (shPU.1), upregulation of CITED2 (CITED2) or a combination of 45 
both (shPU.1/CTED2). Samples with similar levels of SPI1 downregulation were pooled and an lumina 46 
BeadChip array was performed with 2 replicates. (C) Levels of SPI1 (PU.1) downregulation and CITED2 47 
upregulation of transduced CB cells applied to the Ilumina BeadChip array were analyzed by Q-PCR. Error 48 
bars indicate s.d. of Q-PCR triplicates. 49 
 50 
 51 
Supplementary Table S1  52 
Table lists probesets that were found differentially expressed in shPU.1/CITED2- transduced CD34+ cord 53 
blood cells compared to control transduced cells in an Ilumina BeadChip array. 54 
Unique to 
shPU.1/CITED2  
Common with  
CITED2 
Common with  
shPU.1 
Common in  
all groups 
ProbeID Gene Symbol ProbeID Symbol ProbeID Symbol ProbeID Symbol 
3610626 ADM2 2850041 B3Gn-T6 7330102 CSMD1 3710722 CCDC50 
4390523 AGAP7 4060632 C17orf87 1660689 GRB14 2690328 LOC647357 
2510368 ARID4A 3940435 EMP1 6330767 HDAC2 1400653 LOC651075 
7650209 BMF 5810577 FGA 430403 HOXB6 1240139 LOC651680 
3940152 C22orf40 1260341 IL13RA1 4880192 LOC100132771 110411 LOC653701 
3870441 CAPN3 360672 LOC100130928 2600095 LOC165186 7650392 MIR1267 
6220382 CD68 5670176 LOC642003 580575 LOC255620 4290450 PIK3R1 
4040022 CD86 6450358 LOC644641 4640136 LOC648863 5260433 PMCHL1 
2470196 DNAJB5 4590192 LOC645165 2690010 LOC650620 4830632 SLC7A7 
940639 ERP27 2260608 LOC649422 3520240 LOC651137 5720682 TMEM176A 
60307 FCF1 5670450 PURG 3120731 LOC653643 3610020   
6040598 GSDMB 1440730 SNORA29 6620725 PPAP2C 1430494   
4890279 HIST2H4A 450682 SNORA49 1340541 RGPD5 3850369   
3870102 HNMT 4180195 SP6 1400121 SLCO2B1 
  2060553 HYALP1 630722 TBX19 4880519 SPO11 
  5890021 IGSF11 1710273   2760242 TIAM1 
  2470743 KMO 1030243   1300026   
  610037 LAMA1 1990093   6770646   
  3180609 LOC100008588 3460519   6960753   
  6290142 LOC100008589 7560142   
    
2510446 LOC100130276 1070056   
    2750382 LOC100133916 2650048   
    6040386 LOC100134539 
      5960240 LOC100134634 
      1400717 LOC121456 
      240204 LOC151457 
      1580082 LOC158572 
      5860255 LOC284296 
      7150082 LOC285296 
      6760093 LOC440386 
      2450326 LOC642047 
      1820519 LOC642838 
      2850246 LOC643713 
      1010543 LOC643888 
      2000369 LOC644191 
      5290685 LOC645183 
      3870731 LOC645722 
      7560484 LOC647827 
      4810717 LOC650111 
      5910674 LOC650698 
      6370192 LOC728288 
      3140358 LOC728787 
      5700736 LOC729081 
      3520259 LOC730202 
      50332 MDFIC 
      4810114 MGC12982 
      70669 MIR1224 
      990328 MS4A7 
      3990477 MTHFR 
      2480452 MYF5 
      70008 NCF2 
      2650113 NR1I2 
      20068 OTUD1 
      2340301 PION 
      2070592 PPAPDC1A 
      2630519 RSHL3 
      1410440 SHC2 
      4180647 SHPRH 
      840189 SMTN 
      1300349 SOCS4 
      2370368 SON 
      
 55 
 56 
Supplementary Table S2  57 
Table lists primer sequences that have been used for Q-PCR. 58 
name forward primer 5’-3’ reverse primer 5’-3’ 
4120475 SOX15 
      7570670 SPIN1 
      4590767 SPRR1B 
      2350424 SUV420H2 
      4180521 TMEM63B 
      7040348 TMLHE 
      4830273 TWF1 
      5570546 U2AF1L4 
      1010500 UGP2 
      780180 USP9X 
      610438   
      6510739   
      4830300   
      3940609   
      2000709   
      670725   
      7380593   
      4490139   
      5090102   
      1260470   
      6480025   
      830112   
      3120300   
      1580070   
      630615   
      3360170   
      7610427   
      5290433   
      4050296   
      240259   
      4670491   
      1990392   
      7560402   
      
hHPRT AGTTCTGTGGCCATCTGCTTAG CGCCCAAAGGGAACTGATAGTC 
hRPL27 TCCGGACGCAAAGCTGTCATCG TCTTGCCCATGGCAGCTGTCAC 
hRPS11 AAGATGGCGGACATTCAGAC AGCTTCTCCTTGCCAGTTTC 
hCITED2 CTTTGCACGCCAGGAAGGTC CGCCGTAGTGTATGTGCTCG 
hSPI1 (PU.1) GCGACCATTACTGGGACTTC ATGGGTACTGGAGGCACATC 
mSPI1 (PU.1) GCCTCAGTCACCAGGTTTCC CCTTGTCCACCCACCAGATG3 
mHPRT AGTCCCAGCGTCGTGATTAG CCAGCAGGTCAGCAAAGAAC 
mB2M TGACCGGCCTGTATGCTATC GATCCCAGTAGACGGTCTTG 
 59 
Supplementary Material and Methods 60 
 61 
Lentiviral transduction 62 
Human CITED2 cDNA was obtained through Addgene (plasmid 21487) and cloned into the multiple 63 
cloning site of either pRRL-SFFV-IRES-tNGFR or pRRL-SFFV-IRES-EGFP [33]. Vectors containing shRNA 64 
against SPI1 (PU.1) were obtained from GE Healthcare Dharmacon (#V3SVHS06_8494848) and the 65 
hairpin containing region was cloned into the pGIPZ-SFFV-EGFP-shRNAmir backbone using the MluI and 66 
NotI restriction enzyme sites. Constructs for combined CITED2 overexpression and PU.1 downregulation 67 
where obtained by cloning the shRNAmir cassette from the pGPIZ-SFFV-EGFP-shRNAmir vector into the 68 
pRRL-SFFV-IRES-mCherry backbone. Sequences and plasmids are available upon request. Lentiviral 69 
particles were produced as described before.[43] After 24 hours, medium was changed to HPGM and 70 
after 12 hours, supernatant containing lentiviral particles was harvested, concentrated using CentriPrep 71 
Ultracel YM-50 Filter Units (Merck Millipore) and stored at −80°C. Cells were transduced with lentiviral 72 
particles in the presence of 4 μg/ml polybrene in 2 consecutive rounds of 12 hours. During transduction, 73 
human CD34+ cells were kept in HPGM supplemented with hSCF (Novoprotein), hFLT3 ligand (Celldex) 74 
and Npllate (Amgen) (100 ng/ml each). Murine bone marrow cells were kept in StemSpan SFEM 75 
(Stemcell Technologies) supplemented with 100 ng/ml mSCF (PepProtech), 100ng/ml hFLT3 ligand 76 
(Celldex), 100ng/ml Nplate (Amgen) and 20 ng/ml mIL-3 (PepProtech). Cells were sorted 3 days after 77 
transduction on a MoFLo XDP or Astrios (DakoCytomation, Carpinteria, CA, USA) and applied to 78 
subsequent assays. 79 
RNA isolation and Q-PCR  80 
Total RNA was isolated using the RNeasy Micro Kit (QIAGEN) following manufacturer’s instructions and 81 
reverse transcriped using the iScript cDNA synthesis kit (Bio-Rad). Real-Time PCR was performed on a 82 
CFX Connect System (Bio-Rad) using the SsoAdvanced SYBR Green Supermix (Bio-Rad). Data were 83 
quantified using CFX Manager software (Bio-Rad) and normalized to values of the housekeeping gene 84 
RPS11, RPL27, HPRT or B2M. Primer sequences are listed in Supplementary Table S2. 85 
FACS analysis 86 
Cells were sorted on a MoFLo XDP or Astrios (DakoCytomation, Carpinteria, CA, USA). All FACS analyses 87 
were performed on an LSRII (Becton Dickinson) flowcytometer and data was analyzed using FlowJo 88 
software. Murine lineage negative cells were selected using the Alexa Fluor 700 anti-mouse lineage 89 
cocktail (Biolegend, Uithoorn, The Netherlands, #133313). Antibodies used for flow cytometry of murine 90 
cells were: Alexa Fluor 488 anti-mouse Ly-6G/Ly-6C (Gr-1) (Biolegend, #108419), PE anti-mouse CD117 91 
(c-kit) (Biolegend, #105807), Brilliant Violet 421 anti-mouse Ly6A/E (Sca-1) (Biolegend, #108127), PE/Cy7 92 
anti-mouse/human CD11b (Biolegend, #101215). 93 
